Core Viewpoint - The stock of Maide Medical (688310) has shown a slight increase of 1.9% on October 31, 2025, closing at 19.33 yuan, with notable fluctuations in capital flow indicating mixed investor sentiment [1][2]. Financial Performance - For the first three quarters of 2025, Maide Medical reported a main revenue of 225 million yuan, a year-on-year increase of 2.31%, and a net profit attributable to shareholders of 8.84 million yuan, up 15.82% year-on-year [3]. - In Q3 2025, the company achieved a single-quarter main revenue of 83.64 million yuan, reflecting a significant year-on-year increase of 54.38%, and a net profit of 2.79 million yuan, which is a remarkable rise of 224.07% year-on-year [3]. Capital Flow Analysis - On October 31, 2025, the net outflow of main funds was 1.87 million yuan, accounting for 3.32% of the total transaction amount, while retail investors saw a net inflow of 664,600 yuan, representing 1.18% of the total transaction amount [1][2]. - Over the past five days, the stock has experienced fluctuations in capital flow, with significant net inflows and outflows from different investor categories [2]. Industry Comparison - Maide Medical's total market value stands at 3.213 billion yuan, which is below the industry average of 7.798 billion yuan, ranking 205th out of 269 in the specialized equipment industry [3]. - The company's price-to-earnings ratio (P/E) is 272.7, significantly higher than the industry average of 146.16, indicating a potential overvaluation compared to peers [3]. Company Overview - Maide Medical specializes in the research, production, sales, and service of medical consumables and intelligent equipment, integrating technology in medical device processes, automation, and software to provide comprehensive solutions for medical consumable manufacturers [3].

Core Viewpoint - Midea Medical, established in 2003 and listed in 2019, specializes in the research, production, and sales of medical consumables and intelligent equipment, holding several patents in the field [1]. Group 1: Business Performance - For Q3 2025, Midea Medical reported revenue of 225 million yuan, ranking 21st among 25 companies in the industry, with the industry leader achieving 3.653 billion yuan [2]. - The net profit for the same period was -5.46 million yuan, placing the company 18th in the industry, while the top performer reported a net profit of 417 million yuan [2]. Group 2: Financial Ratios - As of Q3 2025, Midea Medical's debt-to-asset ratio was 29.86%, lower than the industry average of 35.98% [3]. - The gross profit margin for Q3 2025 was 40.19%, which is above the industry average of 33.21% [3]. Group 3: Executive Compensation - The chairman, Lin Junhua, received a salary of 1.3803 million yuan in 2024, an increase of 909,300 yuan from the previous year [4]. Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 19% to 4,528, while the average number of shares held per shareholder decreased by 15.97% to 36,700 shares [5]. Group 5: Future Outlook - According to Guosheng Securities, Midea Medical's performance in the first half of 2025 declined due to fluctuations in downstream demand, but showed significant improvement in Q2 [6]. - The company has a strong order backlog for new products, with 21 units of drug-device combination products expected to drive growth [6]. - Revenue projections for 2025 to 2027 are 501 million, 606 million, and 734 million yuan, with corresponding net profits of 80 million, 108 million, and 131 million yuan, indicating substantial growth [6].

Core Viewpoint - On October 30, 2025, the company will hold a staff representative meeting where Mr. Xie Yunbo has been elected as the employee representative director of the fifth board of directors through democratic discussion and voting by the attending employee representatives [1] Group 1 - The company announced the date of the staff representative meeting as October 30, 2025 [1] - Mr. Xie Yunbo was elected as the employee representative director [1] - The election process involved democratic discussion and voting among employee representatives [1]

证券代码：688310 证券简称：迈得医疗 公告编号：2025-044 迈得医疗工业设备股份有限公司 董事会 迈得医疗工业设备股份有限公司 关于选举第五届董事会职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 迈得医疗工业设备股份有限公司（以下简称"公司"）于2025年10月30日召开 2025年第一次临时股东大会，审议通过了《关于取消监事会、调整董事会人数、 修订〈公司章程〉并办理工商变更登记的议案》。根据修订后的《公司章程》， 公司董事会设职工代表董事1名，由公司职工代表大会、职工大会或者其他形式 民主选举产生。 公司于2025年10月30日召开职工代表大会，经与会职工代表民主讨论、表决， 选举谢云波先生（简历见附件）为公司第五届董事会职工代表董事。本次职工代 表大会选举产生的职工代表董事，将与公司2024年年度股东大会选举产生的董事 共同组成公司第五届董事会，任期自本次职工代表大会审议通过之日起至第五届 董事会任期届满之日止。 上述职工代表董事符合《公司法》等法律法规和《公司章程》规定的任职条 件。 ...

上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于迈得医疗工业设备股份有限公司 2025 年第一次临时股东大会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于迈得医疗工业设备股份有限公司 2025 年第一次临时股东大会的法律意见书 致：迈得医疗工业设备股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受迈得医疗工业设备股份 有限公司（以下简称"公司"）的委托，就公司召开 2025 年第一次临时股东大 会（以下简称"本次股东大会"）的有关事宜，根据《中华人民共和国公司法》 （以下简称"《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"） 等相关法律、法规和规范性文件以及《迈得医疗工业设备股份有限公司章程》（以 下简称"《公司章程》"）等内部规章制度的有关规定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（ ...

一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 10 月 30 日 （二） 股东大会召开的地点：浙江省玉环市沙门镇滨港工业城迈得医疗工业设 备股份有限公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： 证券代码：688310 证券简称：迈得医疗 公告编号：2025-043 迈得医疗工业设备股份有限公司 2025 年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 | 1、出席会议的股东和代理人人数 | 18 | | --- | --- | | 普通股股东人数 | 18 | | 2、出席会议的股东所持有的表决权数量 | 109,156,259 | | 普通股股东所持有表决权数量 | 109,156,259 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 66.7103 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 66.7103 ...

证券代码：688310 证券简称：迈得医疗 公告编号：2025-045 迈得医疗工业设备股份有限公司 迈得医疗工业设备股份有限公司（以下简称"公司"）第五届董事会第六次会 议（以下简称"本次会议"）于 2025 年 10 月 30 日以现场加通讯的方式在公司会 议室召开。本次会议于 2025 年第一次临时股东大会结束后，通知公司第五届董 事会全体董事参加会议，经全体董事同意，豁免了本次会议通知关于时限的要求， 召集人已在会议上作出说明。本次会议由董事长林军华先生主持，应出席会议董 事 8 人，实际出席会议董事 8 人。本次会议的召开符合《中华人民共和国公司法》 等法律、行政法规以及《迈得医疗工业设备股份有限公司章程》（以下简称"公 司章程"）的相关规定。 二、董事会会议审议情况 经与会董事审议表决，通过了如下议案： 第五届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 表决结果：同意：8 票；反对：0 票；弃权：0 票。 (二)审议通过了《关于确认董事会审计委员会成员和召集 ...

Market Overview - The automation equipment sector experienced a slight decline of 0.05% on the previous trading day, with Xinjing Intelligent leading the drop [1] - The Shanghai Composite Index closed at 3988.22, down 0.22%, while the Shenzhen Component Index closed at 13430.1, down 0.44% [1] Stock Performance - Notable gainers in the automation equipment sector included: - Tianzhong Precision Machinery (300461) with a closing price of 21.39, up 10.66% and a trading volume of 147,800 shares, totaling 308 million yuan [1] - Weichuang Electric (688698) closed at 88.75, up 9.47% with a trading volume of 100,400 shares, totaling 850 million yuan [1] - Dameng Technology (603025) closed at 20.56, up 6.36% with a trading volume of 614,100 shares, totaling 1.233 billion yuan [1] - Conversely, Xinjing Intelligent (301112) saw a significant decline of 13.96%, closing at 52.27 with a trading volume of 121,400 shares, totaling 667 million yuan [2] - Other notable decliners included: - Maid Medical (688310) down 5.47% to 19.88 [2] - Guangyun Da (300227) down 5.32% to 9.96 [2] Capital Flow - The automation equipment sector experienced a net outflow of 1 billion yuan from institutional investors, while retail investors saw a net inflow of 704 million yuan [2] - The capital flow for specific stocks showed: - Huichuan Technology (300124) had a net inflow of 95.57 million yuan from institutional investors [3] - Weichuang Electric (688698) saw a net inflow of 78.95 million yuan from institutional investors [3] - Jietong Technology (603025) had a net inflow of 41.88 million yuan from institutional investors [3]

Core Viewpoint - Midea Medical experienced a decline of 5.33% in stock price, reaching 19.91 CNY per share, with a total market capitalization of 3.309 billion CNY as of October 28 [1] Company Overview - Midea Medical Industrial Equipment Co., Ltd. is located in Yuhuan City, Zhejiang Province, established on March 10, 2003, and listed on December 3, 2019 [1] - The company's main business involves the research, production, sales, and service of medical consumable intelligent equipment [1] - Revenue composition includes: 48.75% from safe infusion products, 26.27% from blood purification, and 24.98% from other categories [1] Shareholder Information - Among the top circulating shareholders, one fund from Huaxia Fund holds a significant position, having reduced its holdings by 1.0661 million shares in Q3, now holding 2.6036 million shares, which is 1.57% of circulating shares [2] - The Huaxia Industry Prosperity Mixed A Fund (003567) was established on February 4, 2017, with a current scale of 7.261 billion CNY and a year-to-date return of 56.47%, ranking 837 out of 8155 in its category [2] - The fund manager, Zhong Shuai, has a tenure of 5 years and 94 days, with the best fund return during this period being 177.53% and the worst being -2.4% [2]

Core Insights - Midea Medical (688310.SH) reported its Q3 2025 results, revealing that as of October 27, 2025, six institutional investors held a total of 14.056 million shares, representing 8.46% of the company's total equity. This marks a decrease of 1.83 percentage points in institutional ownership compared to the previous quarter [1] Group 1: Institutional Investors - Six institutional investors disclosed their holdings in Midea Medical, with a total shareholding of 14.056 million shares, accounting for 8.46% of the total equity [1] - The institutional ownership decreased by 1.83 percentage points compared to the previous quarter [1] Group 2: Public Funds - One public fund, Huaxia Industry Prosperity Mixed A, reported a decrease in holdings, with a reduction of 0.64% compared to the previous quarter [2] - Two new public funds were disclosed this quarter, including the交银稳健配置混合 and 交银科技创新灵活配置混合A [2] - A total of 49 public funds were not disclosed this quarter, including several notable funds such as Huaxia Vision Growth One-Year Holding Mixed A and Guotai Xinge Youxuan One-Year Holding Mixed A [2] Group 3: Social Security Funds - One social security fund, Huaxia Fund Management Co., Ltd. - Social Security Fund 422 Combination, reported a decrease in holdings, with a reduction of 0.34% compared to the previous quarter [2]